Mumbai-based drugmaker Lupin has received a tentative approval from the US health regulator Food and Drug Association (FDA) for its generic drug Silodosin, used for the treatment of non-cancerous enlargement of the prostate gland. Meanwhile, Lupin's US subsidiary has also received a tentative approval to market its generic anti-bacterial moxifloxacin hydrochloride tablets in the American market.